Comparative Pharmacology
Head-to-head clinical analysis: CEFMAX versus CEFPROZIL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CEFMAX versus CEFPROZIL.
CEFMAX vs CEFPROZIL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
CEFMAX (cefepime) is a fourth-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), specifically PBP-3 in Gram-negative bacteria and PBP-1a/1b in Gram-positive bacteria, thereby disrupting peptidoglycan cross-linking and leading to cell lysis. It has zwitterionic properties facilitating rapid penetration through Gram-negative outer membranes and is relatively resistant to hydrolysis by many beta-lactamases, including AmpC beta-lactamases.
Cefprozil, a second-generation cephalosporin, exerts bactericidal activity by binding to penicillin-binding proteins (PBPs) and inhibiting bacterial cell wall synthesis, leading to cell lysis.
1-2 g IV/IM every 8-12 hours; maximum 6 g/day.
250-500 mg orally every 12 hours for 10 days; for pharyngitis/tonsillitis: 500 mg orally every 24 hours for 10 days.
None Documented
None Documented
Clinical Note
moderateCefprozil + Picosulfuric acid
"The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Cefprozil."
2–4 hours in adults with normal renal function; prolonged to 20–40 hours in severe renal impairment (CrCl <10 mL/min).
1.2-1.4 hours in adults with normal renal function; prolonged to 5-6 hours in severe renal impairment (CrCl <30 mL/min).
Primarily renal (80–90% unchanged via glomerular filtration and tubular secretion); biliary/fecal elimination accounts for <5%.
Renal (primarily), approximately 60-70% unchanged in urine; biliary/fecal excretion accounts for <10%.
Category C
Category A/B
Cephalosporin Antibiotic
Cephalosporin Antibiotic